Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1996-11-22
1999-12-28
Celsa, Bennett
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
530330, 530331, A61K 3806, A61K 3807, C07K 508, C07K 510
Patent
active
060081961
DESCRIPTION:
BRIEF SUMMARY
BACKGROUND OF THE INVENTION
This invention relates to compounds which are inhibitors of elastase, particularly human neutrophil elastase, useful for a variety of physiological and end-use applications, and to processes for making said inhibitors.
Human neutrophil elastase has been implicated as an agent contributing to the tissue destruction associated with a number of inflammatory diseases such as chronic bronchitis, cystic fibrosis, and rheumatoid arthritis. J. L. Malech and J. I. Gallin, New Engl. J. Med., 317(11), 687 (1987). Elastase possesses a broad range of proteolytic activity against a number of connective tissue macromolecules including elastin, fibronectin, collagen, and proteoglycan. The presence of the enzyme elastase may contribute tc the pathology of these diseases.
Normal plasma contains large quantities of protease inhibitors that control a variety of enzymes involved in connective tissue turnover and inflammation. For example, .alpha.-1-proteinase inhibitor (.alpha.-1-P.sub.1) is a serine protease inhibitor that blocks the activity of elastase. .alpha.-1-P.sub.1 has received considerable interest because reduction in plasma levels to less than 15% of normal is associated with the early development of emphysema. In addition to plasma derived protease inhibitors, secretory fluids, including bronchial, nasal, cervical mucus, and seminal fluid contain an endogenous protease inhibitor called secretory leukoprotease inhibitor (SLP.sub.1) that can inactivate elastase and is believed to play an important role in maintaining the integrity of the epithelium in the presence of inflammatory cell proteases. In certain pathological states .alpha.-1-P.sub.1 and SLP.sub.1 are inactivated by neutrophil oxidative mechanisms allowing the neutrophil proteases to function in an essentially inhibitor-free environment. For example, bronchial lavage fluids from patients with adult respiratory distress syndrome (ARDS) have been found to contain active elastase and .alpha.-1-P.sub.1 that had been inactivated by oxidation.
In addition to oxidative mechanisms, neutrophils possess non-oxidative mechanisms for eluding inhibition by antiproteases. Neutrophils from patients with chronic granulomatous disease are capable of degrading endothelial cell matrices in the presence of excess .alpha.-1-P.sub.1. There is considerable in vitro evidence that stimulated neutrophils can tightly bind to their substrates such that serum antiproteases are effectively excluded from the microenvironment of tight cell-substrate contact. The influx of large numbers of neutrophils to an inflammatory site may result in considerable tissue damage due to the proteolysis that occurs in this region.
Applicants have determined that elastase is one of the primary neutrophil proteases responsible for cartilage matrix degeneration as measured by the ability of neutrophil lysate, purified elastase and stimulated neutrophils to degrade cartilage matrix proteoglycan. Furthermore, applicants have previously discovered peptide derivatives useful as elastase inhibitors, exerting valuable pharmacological activities. For example, peptide derivatives useful as elastase inhibitors wherein the terminal carboxyl group has been replaced by a pentafluoroethylcarbonyl (--C(O)C.sub.2 F.sub.5)group and in which the N-terminal amino acid is substituted with various protecting groups are disclosed in European Patent Application OPI No. 0529568, inventors Peet et al., with a publication date of Mar. 3, 1993 and European Patent Application OPI No. 0410411, inventors Bey et al., with a publication date of Jan. 30, 1991. Because of new processes for making perfluoroalkylcarbonyl peptides, Applicants have recently discovered heptafluoropropylcarbonyl and nonaflurobutylcarbonyl moieties of elastase inhibitors.
SUMMARY OF THE INVENTION
The present invention relates to compounds having the following formula I NO.1) derivative, Pro, Ind, Tic or Tca, or Lys substituted on its epsilon amino group with a morpholino-B-group or Orn substituted on its delta amino group with a mo
REFERENCES:
patent: 4277395 (1981-07-01), Bey et al.
patent: 4518528 (1985-05-01), Rasnick
patent: 4623639 (1986-11-01), Hassall et al.
patent: 4629724 (1986-12-01), Ryono et al.
patent: 4636489 (1987-01-01), Seemuller et al.
patent: 4643991 (1987-02-01), Digenis et al.
patent: 4855303 (1989-08-01), Hoover
patent: 4873221 (1989-10-01), Trainor
patent: 4880780 (1989-11-01), Trainor et al.
patent: 4910190 (1990-03-01), Bergeson et al.
patent: 4935405 (1990-06-01), Hoover et al.
patent: 5055450 (1991-10-01), Edwards et al.
patent: 5114927 (1992-05-01), Schirlin
patent: 5162307 (1992-11-01), Digenis et al.
patent: 5221665 (1993-06-01), Skiles
patent: 5478811 (1995-12-01), Peet et al.
patent: 5496927 (1996-03-01), Kolb et al.
patent: 5510333 (1996-04-01), Angelastro et al.
Sham et al, FEB 05016, vol. 220, No. 2, pp. 299-301 (1987).
Travis et al, Am. Rev. Respir, Dis. 143: 1412-1415, (1991).
Eleventh American Peptide Symposium--Jul. 9-14, 1989.
Petrillo et al, Annual Reports in Medicinal Chemistry 25, pp. 51-60.
Chemical Abstracts.
Mehdi et al, Biochemical and Biophysical Research Communications, vol. 166, No. 2, pp. 595-600 (1990).
M.R. Angelastro et al., Bioorganic & Medicinal Chem Let, vol. 3, No. 4 pp. 525-530, (1993).
Peet et al, J. Med. Chem. 33, pp. 394-407 (1990).
Durham et al, J. Pharm. Exp. Ther., vol. 270, No. 1, pp. 185-191 (1994).
Imperiali et al, Biochemistry 25, 3760-3767, (1986).
Skiles et al, Journal of Medicinal Chemistry, vol. 35, No. 4, pp. 641-661 (1992).
Repine et al, J. Med Chem. 34, pp. 1935-1943 (1991).
Ueda et al, Biochem. J. 265 pp. 539-545 (1990).
Steinmeyer et al, Forsch./Drug Res. 41, (l) Nr. (1991).
McWherter et al, Biochemistry 28, pp. 5708-5713 (1989).
Reilly et al, Biochemica et Biophysica Acta. 621 pp. 147-157, (1980).
Najajima et al, Journal of Biological Chemistry, vol. 254, pp. 4027-4031 (1979).
Rice et al, Science, vol. 249, pp. 178-181.
Travis, The American Journal of Medicine, vol. 84, Supl 6A pp. 37-42 (1988).
M.R. Angelastro et al., J. Org. Chem. vol. 54, pp. 3913-3916, (1989).
S. Mehdi, Biogorganic Chem., vol. 21, pp. 249-259, (1993).
M.R. Angelastro et al., Tetrahedron Let, vol. 33, No. 23, pp. 3265-3268, (1992).
J.P. Burkhart et al., Tetrahedron Let, vol. 31, No. 10, pp. 1385-1388, (1990).
Doherty et al, Int. J. Immunopharmac vol. No. 7, pp. 787-795, (1990).
Shah et al, pp. 3745-3754.
Snider, Eur, J. Respir. 69, suppl 146, 17-35, (1986).
Malech et al, Medical Intellegence vol. 317, No. 11, pp. 687-694.
Fletcher et al, Am Rev Respir Dis 1990, 141:672-677.
Hassall et al, Febs 2444, vol. 183, No. 2, (1985).
Mehdi et al., Biochem. & Biophy. Res. Comm., vol. 166, No. 2, pp. 595-600, (1990).
P.G. Gassman et al., J. Org. Chem. vol. 52, pp. 2481-2490, (1987).
Skiles et al., J. Med. Chem. 1992, 35, pp. 641-662, Inhibition of Human Leukocyte Elastase (HLE) by N-Substituted Peptidyl Trifluoromethyl Ketones1.
Skiles et al., J. Med. Chem. 1992, 35, pp. 4795-4808, Inhibition of Human Leukocyte Elastase by N-Substituted Peptides Containing alpha, alpha-Difluorostatone Residues at P1.
Williams et al., Am. Rev. Respir. Dis. 1991; 144; pp. 875-993.
Kawase et al., Tetahedron Letters, vol. 34, No. 5 pp. 859-862, 1993, "Unexpected Product from the Dakin-West Reaction of N-Acylprolines using Trifluoroacetic Anhydride: A Novel Access to 5- Trifluoromethyl-oxazoles".
Kawase, J. Chem. Soc., Chem. Commun., 1992, pp. 1076-1077, "Unusual Ring Expansion observed during the Dakin-West Reaction of Tetrahydroisoquinoline-1-carboxylic Acids using Trifluoroacetic Anhydride: an Expedient Synthesis of 3-Benzazepine Derivatives bearing a Trifluoromethyl Group".
Bundgaard, Hans, Bioreversible Carriers In Drug Design Theory and Appl., pp. 13, 63-65 (1987).
Powers, J.C., Eleventh American paptide Symposium, Abstracts, The Salk Institute and U. of CA, San Diego (1989) Internal notes taken at meeting.
Angelastro et al, Bioorganic & Medicinal Chemistry Letters, vol. 2, No. 10, pp. 1235-1238 (1992).
Angelastro et al, J. Med. Chem. 33, "Communications to the Ed
Angelastro Michael R.
Burkhart Joseph P.
Curran Timothy T.
Metz Jr. William A.
Peet Norton P.
Celsa Bennett
Gupta Balaram
Hoechst Marion Roussel Inc.
LandOfFree
Perfluoroalkyl ketone inhibitors of elastase and processes for m does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Perfluoroalkyl ketone inhibitors of elastase and processes for m, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Perfluoroalkyl ketone inhibitors of elastase and processes for m will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2382480